Abstract
BackgroundTocilizumab (TCZ), a humanised anti-interleukin (IL)6 receptor antibody, was shown to be therapeutically effective in RA patients but the biological effect of TCZ on the immune response was not fully...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
